Literature DB >> 35438363

Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.

Fengjie Xia1, Jiao Lyu1, Jie Peng1, Peiquan Zhao2.   

Abstract

PURPOSE: To evaluate the retinal vascularization of repeated intravitreal ranibizumab (IVR) for reactivated retinopathy of prematurity (ROP) treated with IVR monotherapy.
METHODS: The retrospective study reviewed ROP infants who accepted IVR injection as the first treatment in our department from January 2017 to December 2018. The ratio of the distance from the center of the optic disc to the border of the vascularized zone (DB) to the distance from the center of the disc to the fovea (DF) was used for the vascular outgrowth analysis.
RESULTS: Seventy-eight infants were included in the study. A total of 54.3% of the reactivated ROP patients could achieve complete vascularization after repeated IVR injections. Gestational age (GA) > 29 weeks and a temporal DB/DF ratio ≥ 3 in the first IVR were potential predictors for complete retinal vascularization after IVR monotherapy. The temporal DB/DF ratio ≥ 3.6 in the second IVR injection was a potential predictor for complete retinal vascularization after repeated IVR for ROP reactivation.
CONCLUSIONS: Reactivated ROP after IVR monotherapy can be treated successfully with repeated IVR injections. GA and temporal DB/DF ratio are potential predictors of complete retinal vascularization in ROP infants treated with IVR.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  ROP reactivation; Ranibizumab; Retinopathy of prematurity; Risk factors; Vascular development

Mesh:

Substances:

Year:  2022        PMID: 35438363     DOI: 10.1007/s00417-022-05628-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  28 in total

1.  Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.

Authors:  Emine Alyamaç Sukgen; Yusuf Koçluk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-11-05       Impact factor: 3.117

2.  Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.

Authors:  Andreas Stahl; Tim U Krohne; Nicole Eter; Isabel Oberacher-Velten; Rainer Guthoff; Synke Meltendorf; Oliver Ehrt; Sabine Aisenbrey; Johann Roider; Heinrich Gerding; Claudia Jandeck; Lois E H Smith; Johanna M Walz
Journal:  JAMA Pediatr       Date:  2018-03-01       Impact factor: 16.193

Review 3.  Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.

Authors:  Deborah K VanderVeen; Sule U Cataltepe
Journal:  Semin Perinatol       Date:  2019-05-10       Impact factor: 3.300

4.  Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.

Authors:  Yong Cheng; Xuemei Zhu; Dandan Linghu; Jianhong Liang
Journal:  Acta Ophthalmol       Date:  2020-05-08       Impact factor: 3.761

5.  Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.

Authors:  Jiao Lyu; Qi Zhang; Chun-Li Chen; Yu Xu; Xun-Da Ji; Jia-Kai Li; Qiu-Jing Huang; Pei-Quan Zhao
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-03-01       Impact factor: 4.799

Review 6.  Epidemiology of blindness in children.

Authors:  Ameenat Lola Solebo; Lucinda Teoh; Jugnoo Rahi
Journal:  Arch Dis Child       Date:  2017-05-02       Impact factor: 3.791

7.  Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.

Authors:  Qiujing Huang; Qi Zhang; Ping Fei; Yu Xu; Jiao Lyu; Xunda Ji; Jie Peng; Yi-An Li; Peiquan Zhao
Journal:  Ophthalmology       Date:  2017-04-12       Impact factor: 12.079

8.  Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.

Authors:  Andreas Stahl; Domenico Lepore; Alistair Fielder; Brian Fleck; James D Reynolds; Michael F Chiang; Jun Li; Melissa Liew; Rainer Maier; Qi Zhu; Neil Marlow
Journal:  Lancet       Date:  2019-09-12       Impact factor: 79.321

9.  COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.

Authors:  Guoming Zhang; Mingmin Yang; Jian Zeng; Georgios Vakros; Kangjin Su; Miaohong Chen; Huilin Li; Ruyin Tian; Na Li; Song Tang; Honghui He; Wenjing Tan; Xiangmei Song; Runsen Zhuang
Journal:  Retina       Date:  2017-04       Impact factor: 4.256

10.  Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity.

Authors:  Enzhong Jin; Hong Yin; Yufei Gui; Juan Chen; Jian Zhang; Jianhong Liang; Xiao-Xin Li; Mingwei Zhao
Journal:  J Ophthalmol       Date:  2019-12-31       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.